Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement

Oct 06 2018

• By Mandy Jackson

Vintage Water bokeh background

Related Content

CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah

Jul 13 2018

Kymriah: England Becomes First In Europe To Say Yes To CAR-T

Sep 05 2018

Another CAR-T First: Yescarta Wins Lymphoma Funding In England

Oct 05 2018

Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Jan 23 2018

Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain

Aug 28 2018

Spark's Luxturna Approval Ushers In A New Gene Therapy Era

Dec 19 2017

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Aug 31 2017

Related Companies

Novartis AG

AveXis, Inc.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Spark Therapeutics, Inc.

Gilead Sciences, Inc.

Additional Topics

Reimbursement Regenerative Medicine Launches Cost Effectiveness Pricing Strategies Market Access Commercial BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.